© Brighteon.com All Rights Reserved. All content posted on this site is commentary or opinion and is protected under Free Speech. Brighteon is not responsible for comments and content uploaded by our users.
Reuters
January 6, 2023
The U.S. Food and Drug Administration approved the Alzheimer's drug lecanemab developed by Eisai and Biogen for patients in the earliest stages of the mind-wasting disease.
#News #Reuters #newsfeed #fda #Alzheimer's
Subscribe: http://smarturl.it/reuterssubscribe
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: http://reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en
Mirrored from https://www.youtube.com/watch?v=AkiktWThfog
Sip your way to better gut health with these science-backed, fermented beverages
American Teenagers Are Sleeping Less: Study
How your diet speaks volumes about your health—and how to listen
Review of Dietary Supplement Recommendations for Women Over 40 Examined
The Natural Advantage: Why Eating Spinach in the Morning Is a Simple, Powerful Health Act
The magnesium gap: Why your health depends on looking beyond the breakfast bowl
